-
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
Liu P,
Lin LS,
Hamill TG,
Jewell JP,
Lanza TJ Jr,
Gibson RE,
Krause SM,
Ryan C,
Eng W,
Sanabria S,
Tong X,
Wang J,
Levorse DA,
Owens KA,
Fong TM,
Shen CP,
Lao J,
Kumar S,
Yin W,
Payack JF,
Springfield SA,
Hargreaves R,
Burns HD,
Goulet MT,
Hagmann WK.
The discovery of a structurally distinct cannabinoid-1 receptor (CB1R) positron emission tomography tracer is described. Starting from an acyclic amide CB1R inverse agonist (1) as the lead compound, an efficient route to introduce 18F to the molecule was developed. Further optimization focused on reducing the lipophilicity and increasing the CB1R affinity. These efforts led to the identification of [18F]-16 that exhibited good brain uptake and an excellent signal-to-noise ratio in rhesus monkeys.
PMID: 17608398 [PubMed - indexed for MEDLINE]
-
Related Articles
-
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
[J Pharmacol Exp Ther. 2007]
-
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
[J Med Chem. 2008]
-
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
[Proc Natl Acad Sci U S A. 2007]
-
ReviewThe discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
[Arch Pharm (Weinheim). 2008]
-
ReviewTaranabant, a novel cannabinoid type 1 receptor inverse agonist.
[Curr Opin Investig Drugs. 2008]